Magic mushroom compound and meditation join forces to tackle PTSD

NCT ID NCT07104916

Recruiting now Symptom relief Sponsor: Anthony P King Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a single dose of psilocybin (the active ingredient in magic mushrooms) combined with mindfulness-based therapy can help people with PTSD. Thirty adults with PTSD will receive psilocybin along with either standard support or extra mindfulness training. Researchers will use brain scans and EEG to see how the treatment changes brain activity and connectivity, and whether it reduces PTSD symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If it works, this could point toward a new treatment approach for PTSD that combines a psychedelic drug with mindfulness therapy.
What could go wrong: This is a very small early-phase pilot study with only 30 people, so results may not apply widely. Psilocybin can cause intense psychological effects and is not yet approved for PTSD.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION - MAJOR DEPRESSIVE DISORDER POST-TRAUMATIC STRESS DISORDER

Contacts and locations

Locations

The Ohio State University Medical Center
RECRUITING

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.